ROCAMBOLI STEPHEN 4
4 · TFF Pharmaceuticals, Inc. · Filed Mar 17, 2021
Insider Transaction Report
Form 4
ROCAMBOLI STEPHEN
Director
Transactions
- Exercise/Conversion
Common Stock
2021-03-15$5.00/sh+5,250$26,250→ 35,728 total - Sale
Common Stock
2021-03-15$16.85/sh−20,006$337,101→ 15,722 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-03-15−14,756→ 107,673 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (14,756 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2021-03-15−5,250→ 102,423 totalExercise: $5.00From: 2020-10-29Exp: 2029-10-28→ Common Stock (5,250 underlying) - Exercise/Conversion
Common Stock
2021-03-15$2.50/sh+14,756$36,890→ 30,478 total
Footnotes (3)
- [F1]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F2]23,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vest at an approximate rate of 5,750 every three months thereafter
- [F3]10,948 shares of common stock vested on October 29, 2020 and the remainder of the shares vest at an approximate rate of 2,737 every three months thereafter